MedTrace Logo

Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects

NCT00043966 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2006-07-27

No results posted yet for this study

Summary

The purpose of this study is to compare the safety, tolerability and antiviral activity between once-daily (QD) and twice-daily (BID) dosing of lopinavir/ritonavir and to further characterize the pharmacokinetics of once-daily dosing of lopinavir/ritonavir.

Conditions

  • HIV Infections

Interventions

DRUG

Lopinavir/ritonavir

DRUG

Tenofovir DF

DRUG

Emtricitabine

Sponsors & Collaborators

Principal Investigators

  • Scott Brun, M.D. · Global Project Head, Antiviral Global Project Team

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31

Countries

  • United States
  • Australia
  • France
  • Germany
  • Singapore
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00043966 on ClinicalTrials.gov